Kathleen R Blazer
Overview
Explore the profile of Kathleen R Blazer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chavarri-Guerra Y, Ferrigno-Guajardo A, Villarreal-Garza C, Martinez-Cannon B, Abugattas-Saba J, Fontaine A, et al.
JCO Glob Oncol
. 2024 Oct;
10:e2400097.
PMID: 39481075
Purpose: Women with pathogenic variants (PVs) in breast cancer (BC) and ovarian cancer (OC) associated genes are candidates for cancer risk-reducing strategies. Limited information is available regarding risk-reducing surgeries (RRS)...
2.
Capasso A, Nehoray B, Gorman N, Quinn E, Bucio D, Blazer K
J Genet Couns
. 2024 Mar;
34(1):e1887.
PMID: 38480478
As demand for genetic cancer risk assessment (GCRA) continues to increase, so does the sense of urgency to scale up efforts to triage patients, facilitate informed consent, and order genetic...
3.
Nehoray B, Slavin T, Sun C, Hurley K, King E, Tsang K, et al.
J Genet Couns
. 2022 May;
31(5):1164-1172.
PMID: 35617031
Next-generation tumor tissue sequencing techniques may result in the detection of putative germline pathogenic variants (PVs), raising the possibility that germline cancer predisposition could be identified from archival medical tissue...
4.
Blazer K, Chavarri-Guerra Y, Garza C, Nehoray B, Mohar A, Daneri-Navarro A, et al.
JCO Glob Oncol
. 2021 Jun;
7:992-1002.
PMID: 34181458
Purpose: Genomic cancer risk assessment (GCRA) is standard-of-care practice that uses genomic tools to identify individuals with increased cancer risk, enabling screening for early detection and cancer prevention interventions. GCRA...
5.
Weitzel J, Kidd J, Bernhisel R, Shehayeb S, Frankel P, Blazer K, et al.
Breast Cancer Res Treat
. 2021 Apr;
188(3):759-768.
PMID: 33826040
Purpose: The prevalence, penetrance, and spectrum of pathogenic variants that predispose women to two or more breast cancers is largely unknown. Methods: We queried clinical and genetic data from women...
6.
Chavarri-Guerra Y, Hendricks C, Brown S, Marcum C, Hander M, Segota Z, et al.
J Am Geriatr Soc
. 2019 Apr;
67(5):884-888.
PMID: 31012959
Background/objectives: Women diagnosed with breast cancer (BC) at an older age are less likely to undergo genetic cancer risk assessment and genetic testing since the guidelines and referrals are biased...
7.
Slavin T, Van Tongeren L, Behrendt C, Solomon I, Rybak C, Nehoray B, et al.
J Natl Cancer Inst
. 2018 Apr;
110(10):1059-1066.
PMID: 29618041
Background: In germline genetic testing, variants from understudied ancestries have been disproportionately classified as being of uncertain significance. We hypothesized that the rate of variant reclassification likewise differs by ancestry....
8.
Rebbeck T, Friebel T, Friedman E, Hamann U, Huo D, Kwong A, et al.
Hum Mutat
. 2018 Feb;
39(5):593-620.
PMID: 29446198
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America....
9.
West A, Blazer K, Stoll J, Jones M, Weipert C, Nielsen S, et al.
Fam Cancer
. 2018 Feb;
17(4):495-505.
PMID: 29445900
Comprehensive genomic cancer risk assessment (GCRA) helps patients, family members, and providers make informed choices about cancer screening, surgical and chemotherapeutic risk reduction, and genetically targeted cancer therapies. The increasing...
10.
Weitzel J, Chao E, Nehoray B, Van Tongeren L, LaDuca H, Blazer K, et al.
Genet Med
. 2017 Dec;
20(8):809-816.
PMID: 29189820
Purpose: Blood/saliva DNA is thought to represent the germ line in genetic cancer-risk assessment. Cases with pathogenic TP53 variants detected by multigene panel testing are often discordant with Li-Fraumeni syndrome,...